Overview and Scope
Myelodysplastic syndrome (MDS) is a diverse set of illnesses in which the bone marrow fails to create enough healthy blood cells (red blood cells, white blood cells, and platelets) due to aberrant cell formation and maturation. This condition is caused by uncontrolled cell growth and division that damages tissue. Myelodysplastic syndrome drugs include epoetin alfa, darbepoetin alfa, filgrastim, and other MDS drugs.
Sizing and Forecast
The myelodysplastic syndrome drugs market size has grown rapidly in recent years. It will grow from $2.07 billion in 2023 to $2.28 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to aging population, advancements in diagnostics, chemotherapy-related mds cases, increased cancer survivors, clinical research and drug development.
The myelodysplastic syndrome drugs market size is expected to see strong growth in the next few years. It will grow to $3.26 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to growing geriatric population, advancements in targeted therapies, increased understanding of disease mechanisms, rising awareness and early diagnosis, expansion of oncology research. Major trends in the forecast period include erythropoiesis-stimulating agents optimization, combination therapies, increasing focus on iron chelation therapy, regulatory approvals and market access, patient-centric care models.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/myelodysplastic-syndrome-drugs-global-market-report
Segmentation & Regional Insights
The myelodysplastic syndrome drugs market covered in this report is segmented –
1) By Therapeutic Class: Immunomodulatory Drugs, Hypomethylating Agents, Anti-anemics
2) By Type of Syndrome: Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts
3) By Route of Administration: Oral, Parenteral
4) By Applications: Original, Generics
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers
North America was the largest region in the Myelodysplastic syndrome drugs market in 2023. Asia-Pacific is expected to be the fastest growing region in the global myelodysplastic syndrome drugs market report during the forecast period. The regions covered in the myelodysplastic syndrome drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=10675&type=smp
Major Driver Impacting Market Growth
The increase in the incidence of myelodysplastic syndrome is expected to propel the growth of the myelodysplastic syndrome drug market over the coming years. Myelodysplastic syndrome (MDS) is a group of disorders characterized by abnormal development and maturation of blood cells in the bone marrow. It is a type of blood cancer that primarily affects the production of healthy blood cells. Myelodysplastic syndrome drugs are used in treating myelodysplastic syndrome and involve medications to inhibit or modulate the immune system to lessen the requirement for red blood cell transfusions. For instance, in October 2022, according to the American Journal of Managed Care, a US-based magazine, The prevalence of myelodysplastic syndrome in the USA is estimated to be between 60,000 and 175,000 cases. Therefore, an increase in incidences of myelodysplastic syndrome is driving the growth of the myelodysplastic syndrome drug market.
Key Industry Players
Major companies operating in the myelodysplastic syndrome drugs market report are Amgen Inc., Celgene Corporation, Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Ltd., Onconova Therapeutics Inc., Sun Pharmaceutical Industries Limited, FibroGen Inc., Aprea Therapeutics, Bayer AG, Bristol Myers Squibb, Celator Pharmaceuticals, Crystal Genomics Inc., AbbVie Inc., Astex Pharmaceuticals Inc., Geron Co., Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals Inc., Mylan NV, Novartis AG, Sandoz Inc., Syros Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Agios Pharmaceuticals Inc., Incyte Corporation, Array Biopharma Inc., MEI Pharma Inc.
The myelodysplastic syndrome drugs market report table of contents includes:
1. Executive Summary
2. Myelodysplastic Syndrome Drugs Market Characteristics
3. Myelodysplastic Syndrome Drugs Market Trends And Strategies
4. Myelodysplastic Syndrome Drugs Market – Macro Economic Scenario
5. Global Myelodysplastic Syndrome Drugs Market Size and Growth
.
.
.
31. Global Myelodysplastic Syndrome Drugs Market Competitive Benchmarking
32. Global Myelodysplastic Syndrome Drugs Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Myelodysplastic Syndrome Drugs Market
34. Myelodysplastic Syndrome Drugs Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
